Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry